Table 1 Newer monoclonal antibodies in... | American Society of Hematology

Table 1

Newer monoclonal antibodies in clinical development

Agent	Target	Humanized/chimeric	Direct cell death	ADCC	CDC	Development status
MDX-1342	CD19	Humanized	Yes	Yes	No	Phase 1
XmAb5574	CD19	Humanized	Modest	Yes	No	Phase 1
Ofatumumab	CD20	Humanized	Yes	Yes	Yes	Phase 3
GA-101	CD20	Humanized	Yes	Yes	Modest	Phase 2
PRO131921	CD20	Humanized	Yes	Yes	Yes	Phase 1/2
Veltuzumab	CD20	Humanized	Yes	Yes	Yes	Phase 1/2
LFB-R603	CD20	Chimeric	Yes	Yes	Yes	Phase 1
Lumiliximab	CD23	Primatized	Yes	Yes	Yes	Phase 3
TRU-016	CD37	Humanized	Yes	Yes	No	Phase 1
SGN40	CD40	Humanized	Yes	Yes	No	Phase 1/2
HCD122	CD40	Humanized	No	Yes	No	Phase 1
MDX-1411	CD70	Humanized	No	Yes	No	Phase 1
Milatuzumab	CD74	Humanized	Yes	No	No	Phase 1/2
Ipilimumab	CTLA-4	Humanized	Yes	No	No	Phase 2
Bevacizumab	VEGF	Humanized	No	No	No	Phase 2

Agent	Target	Humanized/chimeric	Direct cell death	ADCC	CDC	Development status
MDX-1342	CD19	Humanized	Yes	Yes	No	Phase 1
XmAb5574	CD19	Humanized	Modest	Yes	No	Phase 1
Ofatumumab	CD20	Humanized	Yes	Yes	Yes	Phase 3
GA-101	CD20	Humanized	Yes	Yes	Modest	Phase 2
PRO131921	CD20	Humanized	Yes	Yes	Yes	Phase 1/2
Veltuzumab	CD20	Humanized	Yes	Yes	Yes	Phase 1/2
LFB-R603	CD20	Chimeric	Yes	Yes	Yes	Phase 1
Lumiliximab	CD23	Primatized	Yes	Yes	Yes	Phase 3
TRU-016	CD37	Humanized	Yes	Yes	No	Phase 1
SGN40	CD40	Humanized	Yes	Yes	No	Phase 1/2
HCD122	CD40	Humanized	No	Yes	No	Phase 1
MDX-1411	CD70	Humanized	No	Yes	No	Phase 1
Milatuzumab	CD74	Humanized	Yes	No	No	Phase 1/2
Ipilimumab	CTLA-4	Humanized	Yes	No	No	Phase 2
Bevacizumab	VEGF	Humanized	No	No	No	Phase 2

ADCC indicates antibody-dependent cell-mediated cytotoxicity; and CDC, complement-dependent cytotoxicity.